Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

March 10, 2027

Study Completion Date

June 30, 2027

Conditions
Migraine
Interventions
DRUG

Lidocaine (drug)

"The study intervention involves the use of 1% cardiac preservative-free lidocaine. Lidocaine is a local anesthetic commonly used in medical procedures to numb a specific area of the body. In this case, the lidocaine is formulated at a concentration of 1% and will be diluted to 50 mL with normal saline.~This treatment is an intra-arterial bilateral lidocaine infusion into the middle meningeal artery (i.e. this is a lidocaine infusion into the brain blood vessels to turn off the pain receptors responsible for causing chronic headaches). Lidocaine is an FDA approved anesthetic (i.e. pain killer) used in common medical practice. Lidocaine, however, has not yet been approved by the FDA for this particular use. For this reason, the use of lidocaine in this study is considered investigational."

PROCEDURE

Lidocaine Procedure

All patient who meet eligibility criteria at their baseline visit will be scheduled for the Liocaine procedure.

Trial Locations (1)

11021

RECRUITING

Neuroscience Institute at Great Neck, Great Neck

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Northwell Health

OTHER